Abstract

This study set out to analyse the potential ability of some 5-hydroxytryptamine (5-HT) receptor ligands widely used in cardiovascular experimental models to interact with vascular α 1-adrenoceptors in the pithed rat. These ligands included: methiothepin, methysergide and metergoline (5-HT 1/5-HT 2); WAY-100635, buspirone, ipsapirone and 8-hydroxy-2-(di- n-propylamino)tetralin (8-OH-DPAT) (5-HT 1A); GR127935 (5-HT 1B/1D); ketanserin, ritanserin, spiperone and pizotifen (5-HT 2); granisetron and metoclopramide (5-HT 3); tropisetron (5-HT 3/5-HT 4); ergotamine (5-HT 1B/1D, 5-ht 5A/5B); clozapine (5-HT 6/5-HT 7); as well as LY215840 and mesulergine (5-HT 2/5-HT 7). For this purpose, the increases in diastolic blood pressure produced by the selective α 1-adrenoceptor agonist, phenylephrine, were analysed before and after the above antagonists or saline. The adrenoceptor antagonist properties of prazosin (α 1) and yohimbine (α 2) were also analysed for comparison. Thus, the phenylephrine-induced vasopressor responses were dose-dependently antagonised with the following apparent rank order of potency by: prazosin ≥ methiothepin > ketanserin > clozapine ≥ lisuride ≫ buspirone; this potency correlates with the affinity of these compounds for α 1-adrenoceptor binding sites. In contrast, the other compounds were either devoid of any blocking effect on — or even potentiated (i.e. lisuride, methysergide, 8-OH-DPAT, granisetron and GR127935) — the responses to phenylephrine. These results show that methiothepin, ketanserin, clozapine, lisuride and buspirone can block α 1-adrenoceptors in the rat systemic vasculature.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.